JP Morgan recently initiated coverage on Exponent with an Overweight/Buy rating, highlighting the firm’s position as a ...
StockStory.org on MSN
Exponent’s (NASDAQ:EXPO) Q4 CY2025: Strong sales
Scientific consulting firm Exponent (NASDAQ:EXPO) reported in Q4 CY2025, with sales up 19.1% year on year to $147.4 million. Its GAAP profit of $0.49 per share was 3.7% above analysts’ consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results